Moreover, an important future task will be to investigate whether methylation of RHCG and TCAF1 can also predict prostate cancer aggressiveness at the time of diagnosis based on analysis of DNBs or even liquid biopsies, in order to guide treatment decisions. This evidence concerns the gene TCAF1 and prostate cancer.